Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data
Ann-Kathrin Blumenröther, Yongxing Fang, Tamara El Saadany, Egle Ramelyte, Omar Hasan Ali, Thomas Kündig, Daniela Mihic-Probst, Sarah Steiner, Alexander Maurer, Reinhard Dummer, Joanna Mangana, Lara V. Maul · 2025
Read Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data by Ann-Kathrin Blumenröther, Yongxing Fang, Tamara El Saadany, Egle Ramelyte, Omar Hasan Ali, Thomas Kündig, Daniela Mihic-Probst, Sarah Steiner, Alexander Maurer, Reinhard Dummer, Joanna Mangana, Lara V. Maul (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785055.txt.
Description
Ann-Kathrin Blumenrother and co-authors report Swiss real world results for treatment given before surgery in advanced melanoma in a 2025 study. Trials had shown that immunotherapy before removal beats the same drugs after, but everyday practice data were missing. The team reviewed all suitable patients treated at a Zurich hospital over two years. Most received one of two trial based immunotherapy regimens, with a small group treated for mucosal melanoma.
About two fifths of patients achieved a major pathologic response, meaning little tumor left in the removed tissue. Rates differed by regimen, with one protocol's group responding most often. Partial responses accounted for another share. Response, survival without events, and safety were the main endpoints. The authors offer the series as real world support for the trial findings.
Catalog record
| CREATOR | Ann-Kathrin Blumenröther, Yongxing Fang, Tamara El Saadany, Egle Ramelyte, Omar Hasan Ali, Thomas Kündig, Daniela Mihic-Probst, Sarah Steiner, Alexander Maurer, Reinhard Dummer, Joanna Mangana, Lara V. Maul |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |